Sugi Predict

Sugi Predict / Compounds / SCHEMBL9769283

SCHEMBL9769283

SCHEMBL9769283

Nc1cc(Cl)c(C(=O)O)c(Cl)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ THRB P10828 2/20 0.50
▸ ALDH1A1 P00352 6/20 0.48
▸ CYP3A4 P08684 5/20 0.48
▸ DPP4 P27487 1/20 0.43
▸ CA1 P00915 1/20 0.39
▸ CA2 P00918 1/20 0.39
▸ TTR P02766 1/20 0.39
▸ NR1H4 Q96RI1 2/20 0.39
▸ TSHR P16473 4/20 0.39
▸ KDM4E B2RXH2 2/20 0.39
▸ HSD17B10 Q99714 2/20 0.39
▸ CASP1 P29466 2/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ TDP1 Q9NUW8 1/20 0.39
▸ HPGD P15428 1/20 0.39
▸ ALOX15 P16050 1/20 0.39
▸ RECQL P46063 1/20 0.39
▸ POLB P06746 1/20 0.38
▸ TP53 P04637 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31460347 0.89 THRB (0.44) THRBALDH1A1CYP3A4DPP4CA1
SCHEMBL8243818 0.87 THRB (0.48) THRBALDH1A1CYP3A4DPP4CA1
SCHEMBL9769361 0.85 THRB (0.41) THRBALDH1A1CYP3A4DPP4CA1
SCHEMBL15233200 0.85 ALDH1A1 (0.48) THRBALDH1A1CYP3A4DPP4NR1H4
SCHEMBL8231253 0.82 THRB (0.39) THRBALDH1A1CYP3A4DPP4CA1
SCHEMBL14266405 0.82 THRB (0.39) THRBALDH1A1CYP3A4DPP4CA1
SCHEMBL9769182 0.80 MAPT (0.39) THRBALDH1A1CYP3A4DPP4NR1H4
SCHEMBL733861 0.80 ALDH1A1 (0.50) ALDH1A1CA1CA2TTRNR1H4
SCHEMBL14511091 0.80 ALDH1A1 (0.52) THRBALDH1A1CYP3A4CA1CA2
SCHEMBL111202 0.79 AKR1C4 (0.54) ALDH1A1CYP3A4DPP4TTRTSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116854628-B Fluopicolide hapten, artificial antigen and antibody as well as preparation methods and application thereof 深圳凯吉星农产品检测认证有限公司 2024-04-12 — — CN claimed
CN-116854628-A Fluopicolide hapten, artificial antigen and antibody as well as preparation methods and application thereof 深圳凯吉星农产品检测认证有限公司 2023-10-10 — — CN claimed
US-3931300-A Process for the production of dichlorobenzoic acids BASF AKTIENGESELLSCHAFT (DT) 1976-01-06 — — US claimed
CN-120136780-A Fluopicolide hapten and artificial antigen as well as preparation methods and applications thereof 中国海关科学技术研究中心 2025-06-13 — — CN disclosed
CN-113195053-B Amino acid compounds and methods of use 普利安特治疗公司 2024-08-30 — — CN disclosed
US-20240270742-A1 SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS PLIANT THERAPEUTICS INC (US) 2024-08-15 — — US disclosed
CN-116854628-B Fluopicolide hapten, artificial antigen and antibody as well as preparation methods and application thereof 深圳凯吉星农产品检测认证有限公司 2024-04-12 — — CN disclosed
US-11952376-B2 Substituted amino acids as integrin inhibitors PLIANT THERAPEUTICS, INC. (US) 2024-04-09 — — US disclosed
CN-116854628-A Fluopicolide hapten, artificial antigen and antibody as well as preparation methods and application thereof 深圳凯吉星农产品检测认证有限公司 2023-10-10 — — CN disclosed
US-11643388-B2 Inhibitors of alpha 2 beta 1 integrin and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-05-09 — — US disclosed
US-11643388-B2 Inhibitors of alpha 2 beta 1 integrin and methods of use thereof THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2023-05-09 — — US disclosed
CN-113195053-A Amino acid compounds and methods of use 普利安特治疗公司 2021-07-30 — — CN disclosed
US-20200109141-A1 AMINO ACID COMPOUNDS AND METHODS OF USE PLIANT THERAPEUTICS, INC. 2020-04-09 — — US disclosed
EP-3229801-B1 FACTOR IXA INHIBITORS MERCK SHARP & DOHME (US) 2020-04-01 — — EP disclosed
US-10189819-B2 Factor IXa inhibitors MERCK SHARP & DOHME, CORP. (US) 2019-01-29 — — US disclosed
US-20180030036-A1 Factor IXa Inhibitors MERCK SHARP & DOHME CORP. (US) 2018-02-01 — — US disclosed
EP-3229801-A1 FACTOR IXA INHIBITORS Merck Sharp & Dohme Corp. (US) 2017-10-18 — — EP disclosed
WO-2016094260-A1 FACTOR IXA INHIBITORS MERCK SHARP & DOHME CORP. (US) 2016-06-16 — — WO disclosed
US-5068436-A Hydrogenation of halonitrobenzenes without dehalogenation E. I. DU PONT DE NEMOURS AND COMPANY (US) 1991-11-26 — — US disclosed
US-3931300-A Process for the production of dichlorobenzoic acids BASF AKTIENGESELLSCHAFT (DT) 1976-01-06 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11643388-B2 Inhibitors of alpha 2 beta 1 integrin and methods of use thereof ITGB1, ITGB2, ITGA2 THRB 403/4885ALDH1A1 399/4885CYP3A4 3609/4885
US-20200109141-A1 AMINO ACID COMPOUNDS AND METHODS OF USE ITGB6, ITGA1, ITGAL THRB 1553/4885ALDH1A1 1981/4885CYP3A4 4072/4885
US-11952376-B2 Substituted amino acids as integrin inhibitors ITGB6, ITGA1, ITGB1 THRB 1877/4885ALDH1A1 2168/4885CYP3A4 4168/4885
US-20240270742-A1 SUBSTITUTED AMINO ACIDS AS INTEGRIN INHIBITORS ITGB6, ITGA1, ITGB1 THRB 1877/4885ALDH1A1 2168/4885CYP3A4 4168/4885
US-20180030036-A1 Factor IXa Inhibitors F9, TFPI, F12 THRB 1987/4885ALDH1A1 634/4885CYP3A4 963/4885
US-10189819-B2 Factor IXa inhibitors F9, TFPI, F12 THRB 1987/4885ALDH1A1 634/4885CYP3A4 963/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.